ArticleInternational journal of molecular sciences2020
Metabolic Syndrome, Clusterin and Elafin in Patients with Psoriasis Vulgaris.
Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- The impact of biologics targeting the IL-17 and IL-23 pathways on metabolic indicators in plaque psoriasis.Archives of dermatological research · 2025Trial
- Biological Treatment of Psoriasis-Data So Far.Pharmaceuticals (Basel, Switzerland) · 2026Review
- The Role of Elafin in the Pathogenesis of Psoriasis.International journal of molecular sciences · 2026Article
- A Multicenter Validation of a Fully Automated Chemiluminescence Immunoassay for Plasma Elafin in Psoriasis Diagnosis and Severity Assessment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- The Role of Selected Proteins in the Pathogenesis of Psoriasis.International journal of molecular sciences · 2025Review
- FLI1 Induces Plaque Psoriasis and Its Inhibition Attenuates Disease Progression.Journal of inflammation research · 2025Article
- Glycosylation Pattern of Serum Clusterin in Psoriatic Arthritis and Rheumatoid Arthritis-The Search for New Diagnostic Glycomarkers.International journal of molecular sciences · 2024Article
- Systematic analysis of serum peptidase inhibitor 3 in psoriasis diagnosis and treatment.Clinical rheumatology · 2024Article
- Psoriasis: What Is New in Markers of Disease Severity?Medicina (Kaunas, Lithuania) · 2024Review
- Exploring the causal relationship between inflammatory cytokines and immunoinflammatory dermatoses: a Mendelian randomization study.Frontiers in medicine · 2024Article
- Genomic Profiling of the Overlap Phenotype between Psoriasis and Atopic Dermatitis.The Journal of investigative dermatology · 2024Article
- Effects of Metabolic Syndrome on Cardiovascular Outcomes of Psoriatic Patients with Coronary Artery Disease: A Single Center Retrospective Cohort Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Article
- The Presence of Psoriasis, Metabolic Syndrome and Their Combination Increases the Serum Levels of CRP and CD5L but Not sCD200R1 and sTLR2 in Participants.Journal of personalized medicine · 2022Article
- Significantly Altered Serum Levels of NAD, AGE, RAGE, CRP, and Elastin as Potential Biomarkers of Psoriasis and Aging-A Case-Control Study.Biomedicines · 2022Article
- Gut Microbiota Dysbiosis and Altered Bile Acid Catabolism Lead to Metabolic Disorder in Psoriasis Mice.Frontiers in microbiology · 2022Article
- Psoriasis: Pathogenesis, Comorbidities, and Therapy Updated.International journal of molecular sciences · 2021Article
- Aging in psoriasis vulgaris: female patients are epigenetically older than healthy controls.Immunity & ageing : I & A · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundPsoriasis is a pathological condition characterized by immune system dysfunction and inflammation. Patients with psoriasis are more likely to develop a wide range of disorders associated with inflammation. Serum levels of various substances and their combinations have been associated with the presence of the disease (psoriasis) and have shown the potential to reflect its activity. The aim of the present study is to contribute to the elucidation of pathophysiological links between psoriasis, its pro-inflammatory comorbidity metabolic syndrome (MetS), and the expression of clusterin and elafin, which are reflected in the pathophysiological "portfolio" of both diseases. MATERIAL AND
methodsClinical examinations (PASI score), ELISA (clusterin, elafin), and biochemical analyses (parameters of MetS) were performed.
resultsWe found that patients with psoriasis were more often afflicted by MetS, compared to the healthy controls. Clusterin and elafin levels were higher in the patients than in the controls but did not correlate to the severity of psoriasis.
conclusionOur data suggest that patients with psoriasis are more susceptible to developing other systemic inflammatory diseases, such as MetS. The levels of clusterin and elafin, which are tightly linked to inflammation, were significantly increased in the patients, compared to the controls, but the presence of MetS in patients did not further increase these levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.